Embodiments herein include coated medical devices and coatings with salt groups. In an embodiment, a coated medical device is included, the coated medical device including a substrate and a polymeric layer disposed over the substrate. The polymeric layer includes a polymer and has an exterior surface. The coated medical device further includes a plurality of salt groups bonded to the polymer of the polymeric layer and disposed on the exterior surface of the polymeric layer. The salt groups can be the reaction product of a reactive group with an acid or base. In an embodiment, a method of making a medical device is included. Other embodiments are also included herein.

Various aspects of the present disclosure are directed toward apparatuses, systems, and methods that include a prosthetic valve. The prosthetic valve may include a jacket configured to cover at least one of gaps, spaces, or interfaces in a frame or between one or more leaflets attached to the frame.

Techniques are provided for controlling delivery of a therapeutic coating to a medical implant device. An identifier of the medical implant device may be received. It may be determined, based at least in part on the first identifier, that the first medical implant device is approved to receive the therapeutic coating. A coating applicator system may be switched from a locked state in which it is prohibited from applying the therapeutic coating to an unlocked state in which it is permitted to apply the therapeutic coating. The coating applicator system may, while in the unlocked state, apply the therapeutic coating to the first medical implant device. After the applying of the therapeutic coating, the coating applicator system may be switched from the unlocked state back to the locked state.

Techniques are provided for controlling delivery of a therapeutic coating to a medical implant device. An identifier of the medical implant device may be received. It may be determined, based at least in part on the first identifier, that the first medical implant device is approved to receive the therapeutic coating. A coating applicator system may be switched from a locked state in which it is prohibited from applying the therapeutic coating to an unlocked state in which it is permitted to apply the therapeutic coating. The coating applicator system may, while in the unlocked state, apply the therapeutic coating to the first medical implant device. After the applying of the therapeutic coating, the coating applicator system may be switched from the unlocked state back to the locked state.

The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.

The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.

Plasma systems for depositing biomolecules, pharmaceutical agents, and other therapeutic active agents onto surfaces are described. The systems may include a plasma device having one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. A particulate delivery system may be used to introduce the active agent(s) as a dry powder into or downstream of the plasma, and to deposit the plasma-treated active agent(s) to produce a coating on a surface. The coating may retain the activity of the active agent(s).

Plasma systems for depositing biomolecules, pharmaceutical agents, and other therapeutic active agents onto surfaces are described. The systems may include a plasma device having one or more electrodes, a gas supply inlet, a plasma outlet exposed to ambient pressure, and an ignition system operatively connected to the electrodes for providing a non-thermal equilibrium plasma within the plasma chamber. A particulate delivery system may be used to introduce the active agent(s) as a dry powder into or downstream of the plasma, and to deposit the plasma-treated active agent(s) to produce a coating on a surface. The coating may retain the activity of the active agent(s).

In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. ##STR00001##

In one aspect, the invention provides compounds of Formula I Formula Ia, Formula Ib, Formula Ic, and Formula Id and salts, hydrates and isomers thereof. In another aspect, the invention provides a method of promoting bone formation in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. The present invention also provides orthopedic and periodontal devices, as well as methods for the treatment of renal disease, diabetes bone loss, and cancer, using a compound of Formula I, Formula Ia, Formula Ib, Formula Ic, or Formula Id. ##STR00001##